Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
News
|
Comment
|
Features
|
Analysis
|
Supplements & Reports
|
People
|
Events
|
Multimedia
|
Science Abstracts
|
OSI eyes third party options after board rejects Astellas bid
Today
OSI Pharmaceuticals ' board has unanimously rejected Astellas 's unsolicited $52 per share cash offer for the company, recommending that OSI shareholders do ...
ACCORD LIPID: Fenofibrates fail to improve cardiovascular outcomes type 2 diabetics
15 March 2010
Hypolipaemic fenofibrates such as Abbott s' TriCor, its next-generation Trilipix and generics, do not improve cardiovascular outcomes in patients with type 2 ...
Plavix gets US "boxed warning" about poor metabolisers
15 March 2010
Bristol-Myers Squibb and Sanofi-Aventis have added a "boxed warning" to the US label for the blockbuster blood thinner Plavix (clopidogrel), in order to warn ...
Pfizer faces disappointment with anticancers after more Phase III failures
12 March 2010
Pfizer is facing more disappointment with the development of some of its most advanced anticancers after Sutent (sunitinib) failed two more Phase III trials in ...
 
Forbion leads Promedior's $12 million series C round
Today
Promedior has raised $12 million in a series C financing round. The clinical-stage US biotechnology company is developing therapies to treat inflammatory and fibrotic diseases. Forbion Capital ...
Lilly to pay up to $335 million for testosterone solution
Today
Lilly is to pay Acrux $50 million up front for the global commercialisation rights to its underarm testosterone solution Axiron. The Australian company will also receive $3 million in the transfer of ...
Ablynx completes funding, raises €50 million
Today
Belgian antibody firm Ablynx has completed its secondary public offering, raising €50 million through the sale of just under 6.7 million new shares at €7.50 each. An over-allotment option of up to ...
EU invests $5.4 million in Grindeks's new facility
Today
Grindeks of Latvia has signed an agreement with the national investment and development agency, under which it will receive funding of Ls2.8 million ($5.4 million) from the European Regional ...
 
No new trials needed in US FDA complete response letter for once-weekly exenatide
15 March 2010
Amylin Pharmaceuticals , Lilly and Alkermes ' type 2 diabetes candidate Bydureon (exenatide for extended-release injectable suspension) – a once-weekly formulation of the twice-daily dosed Byetta – ...
US FDA advisory committees back randomised trials for LABA safety
12 March 2010
The US FDA was established in 1931, but only three years ago did it get the power to order drug makers to conduct safety studies of products that have already been approved and put into general use. ...
Actelion needs to provide more info to FDA for Zavesca in Niemann-Pick disease
12 March 2010
The US FDA has issued Actelion with a complete response letter for its drug Zavesca (miglustat), for the treatment of progressive neurological manifestations in adults and children with Niemann-Pick ...
Takara Bio allies with US university for novel HIV gene therapy
12 March 2010
Takara Bio has signed a collaborative research agreement with the University of Pennsylvania in the US for the co-development of an innovative gene-based therapy for HIV. The Japanese firm will work ...
 
Ranbaxy settles with Takeda on Actos suit
15 March 2010
Ranbaxy Laboratories has settled outstanding patent litigation with Takeda Pharmaceutical Company , allowing it to launch a generic version of Takeda's antidiabetic, Actos (pioglitazone ...
Humira, Enbrel and Remicade are NICE choices for psoriatic arthritis
15 March 2010
NICE , the health technology appraisal body for England and Wales, has given a preliminary green light to treating some psoriatic arthritis patients with Abbott 's Humira (adalimumab) and Wyeth 's ...
Pharma's promotional breach money to be given to Australia's aborigines
15 March 2010
The R&D industry association Medicines Australia is donating A$1 million ($912,997), collected in fines from pharmaceutical companies that breached the marketing code of conduct, to a charity aimed ...
Germany to end free pricing for patented medicines
12 March 2010
Germany's health ministry is planning to introduce compulsory price negotiations for patented drugs between the pharmaceutical industry and health insurers, it confirmed to Scrip. The measure could ...
 
PEOPLE
Two new appointments at Cerulean Pharma Cerulean Pharma, a US biopharmaceutical company focused on nanoparticle-based drugs, has appointed ...
New president for Sandoz's US operations Sandoz , the generics arm of Novartis, has named Don DeGolyer president of US operations and head ...
New appointment as UK pharmacy regulator demerger approaches Preparations for thedemerging of the Royal Pharmaceutical Society of Great Britain (RPSGB) are ...
>> More People News...

EXPERT VIEW
EU must act to save its minor markets for medicines
15 March 2010
Faraz Kermani
The fact that many poor countries globally suffer as a result of the lack of access to life-saving ...

Market Insight: Big pharma hit by Greece's fiscal crisis
09 March 2010

Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of ...

 Market Insight - Fear gives way to prudence a...

How to run clinical trials in the Middle East - why the GCC?
04 March 2010

A grouping of Middle Eastern countries came together under the auspices of the Gulf Co-operation ...

How to run clinical trials in the Middle East - Jordan
04 March 2010

Jordan has a population of 6.35 million and its GDP per capita is $5,000, while its healthcare ...

MULTIMEDIA
Scrip in a minute - week ending March 12th 12 March 2010

Get the Flash Player to see this player.

Private investment round-up: February 2010
15 March 2010
Simon Varcoe
Just as it appeared that the private investment market was beginning to rebound after last year's ...

European Medicines Agency and logos: snakes, DNA and the pestle and mortar
22 December 2009
Elizabeth Sukkar
Logos are said to be an important part of an organisation's branding. Really good logos contribute ...

Face to Face with Sandoz's "growth guy" Jeff George
04 March 2010
Eleanor Malone
Jeff George took over as head of Sandoz, Novartis's generics business, in late 2008. With a big ...

CPhI Worldwide 2009
13 October 2009
Scrip's official preview of CPhI Worldwide, ICSE, P-MEC and BioPh 2009

Scrip's Stock Tracker February 2010
12 March 2010
Ashley Yeo
Talk of dividends being under threat at companies such as Bristol-Myers Squibb , Pfizer and Lilly , ...

EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm